Charles Schwab Investment Management Inc. Buys 3,691 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Charles Schwab Investment Management Inc. increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 293,700 shares of the company’s stock after buying an additional 3,691 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Tarsus Pharmaceuticals worth $16,262,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in shares of Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the period. Ally Bridge Group NY LLC bought a new position in Tarsus Pharmaceuticals in the third quarter worth approximately $10,587,000. Ikarian Capital LLC lifted its holdings in Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after buying an additional 230,000 shares during the period. Finally, Vestal Point Capital LP bought a new stake in Tarsus Pharmaceuticals during the 3rd quarter valued at $7,565,000. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TARS shares. Jefferies Financial Group upped their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reiterated a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $63.67.

Insider Buying and Selling

In other news, General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the transaction, the general counsel now owns 58,057 shares of the company’s stock, valued at $2,687,458.53. The trade was a 5.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 7,131 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now directly owns 70,720 shares of the company’s stock, valued at $3,273,628.80. The trade was a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,542 shares of company stock worth $1,281,173. 8.25% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Trading Up 0.7 %

NASDAQ:TARS opened at $49.91 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm has a fifty day simple moving average of $48.54 and a 200-day simple moving average of $45.06. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a market capitalization of $1.92 billion, a P/E ratio of -13.10 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. On average, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.